default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

Samsung Bioepis, Genentech settle patent dispute on breast cancer biosimilar: source

기사승인 2019.07.04  10:16:31

공유
default_news_ad2

The agreement will allow Samsung Bioepis to distribute, market and sell the biosimilar Ontruzant in the United States, according to the source.

Ontruzant, the breast cancer treatment biosimilar referencing Roche's Herceptin, won approval from the U.S. Food and Drug Administration earlier this year.

Samsung Bioepis is a joint venture between Samsung BioLogics -- a biopharmaceutical unit of South Korea's top conglomerate Samsung Group -- and its U.S. partner Biogen Inc.

Biosimilars are defined by the FDA as products that are "highly similar to an already approved biological product" and have "no clinically meaningful differences in terms of safety and effectiveness from the reference product." (Yonhap)

Headquarters building of Samsung Bioepis Co.in Songdo, west of Seoul.

Son Da-som edt@koreapost.com

<저작권자 © 코리아포스트 무단전재 및 재배포금지>
default_news_ad5
default_side_ad1
default_nd_ad2

인기기사

default_side_ad2

포토

1 2 3
set_P1
default_side_ad3

섹션별 인기기사 및 최근기사

default_side_ad4
default_nd_ad6
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch